Why patients ask about cannabis suppositories

Patients usually arrive at this question after encountering some limitation with more familiar routes. An edible may last too long. Inhalation may be undesirable or impractical. A patient with pelvic or rectal symptoms may simply wonder whether putting the medicine closer to the symptom makes sense.

That question is reasonable. What becomes less reasonable is the leap from “rectal administration can absorb drugs” to “a cannabis suppository will deliver a predictable amount of THC or CBD, with little systemic exposure and mostly local effects.” The current evidence does not support that degree of certainty.

Rectal administration has unusual pharmacokinetics because the venous drainage of the rectum is divided. Drug absorbed from the lower rectum can enter systemic circulation without first traveling through the liver, while absorption higher in the rectum can enter portal circulation. In practical terms, rectal administration can partially bypass hepatic first-pass metabolism. It does not automatically eliminate it.

The more important lesson from cannabis research is that the formulation matters enormously. Ordinary THC, a chemically modified THC prodrug, and a modern engineered cannabis suppository can behave very differently after rectal administration.

What you need

A solid coconut oil base

Use coconut oil that becomes solid when chilled and remains reasonably firm at normal refrigerator temperatures. Standard virgin or refined coconut oil can serve this purpose.

Fractionated coconut oil or MCT oil is different. These products generally remain liquid at room temperature and therefore do not behave like a conventional molded suppository base. If the goal is a firm molded unit, a liquid MCT product should not simply be substituted for solid coconut oil.

A cannabinoid preparation with a known concentration

The dosing calculation is only as good as the information on the starting product. A labeled, oil-compatible cannabis preparation that states cannabinoid concentration in milligrams per milliliter is preferable to home-infused material of uncertain potency.

Avoid assuming that every tincture or extract can simply be mixed into coconut oil. Alcohol-containing tinctures, emulsified products, and complex commercial formulations may behave differently from an oil-based concentrate.

A mold and basic equipment

You will need a clean suppository mold, a heat-safe mixing vessel, a water bath or double boiler, a small syringe or pipette for filling, a stirring tool, and refrigerator or freezer space for setting the mixture.

Mold volumes vary. Before making a medicated batch, determine how much liquid your actual mold holds. One simple method is to fill the cavities with water, measure the total volume, and then wash and dry the mold completely before preparing the oil mixture.

First, calculate the dose correctly

This is the part of a home recipe where errors matter most. Start with the dose you intend to place in each unit, not with the volume of cannabis oil you happen to have.

For example, suppose you intend to prepare 10 suppositories containing 5 mg THC each. The batch therefore requires 50 mg THC in total. If your starting oil contains 100 mg THC per mL, you would need 0.5 mL of that oil. You would then add enough carrier to reach the final volume required to fill your mold.

If the starting product is much more dilute, the volume needed to reach the target cannabinoid dose may become a large fraction of the entire suppository. That can change firmness, mixing behavior, and dose uniformity. This is one reason concentrated, clearly labeled preparations are easier to formulate predictably than dilute oils.

How to make coconut oil cannabis suppositories in 7 steps

Home preparation cannot reproduce the manufacturing controls used in pharmaceutical compounding. The goal here is therefore modest: a clean, carefully measured, small-batch preparation using a starting cannabis product with known potency.

1. Calculate the entire batch before heating anything.
   Determine your intended dose per unit, the number of units, the total cannabinoid required, the concentration of the starting oil, and the total volume your mold will hold.
2. Clean and completely dry the equipment.
   Wash the mold, mixing vessel, stirring tool, and filling syringe or pipette. Any residual water can interfere with a homogeneous oil preparation.
3. Gently melt the coconut oil.
   Warm the carrier in a water bath or double boiler only until it becomes fully liquid. High heat is unnecessary. Avoid direct high-temperature cooking.
4. Add the measured cannabis preparation.
   Remove the carrier from direct heat, add the calculated volume of cannabis oil or concentrate, and mix carefully until the preparation appears uniform.
5. Continue mixing as you fill the mold.
   Use a small syringe or pipette to fill each cavity as evenly as possible. Stir again during filling if the mixture sits long enough to begin cooling or separating.
6. Chill until completely firm.
   Keep the mold level and transfer it to the refrigerator or freezer until the units are solid enough to remove without deforming.
7. Label and store cold.
   Place the finished units in a clean, sealed container and label the preparation with the date, cannabinoid used, starting concentration, and intended milligrams per suppository. Coconut oil softens readily in warm environments, so refrigeration is generally the most practical storage approach.

Coconut oil versus cocoa butter

Cocoa butter has a long history as a pharmaceutical suppository base. Coconut oil is convenient and familiar, but it softens at a substantially lower temperature. Standard coconut oil commonly becomes liquid around 76°F, while cocoa butter generally remains firmer until temperatures closer to body temperature. The exact behavior of cocoa butter depends in part on its crystalline form and preparation history.

The important scientific correction is that suppository bases should not be assumed interchangeable simply because both are fats. A 2025 pharmaceutical formulation study comparing standardized cannabis suppositories made with cocoa butter and Witepsol H15 found differences in physical properties and in vitro THC release. That study did not test homemade coconut-oil products, but it demonstrates the larger point: the carrier can change how a formulation behaves.

Why I would not use the old “0 to 10%” estimate

You may encounter very low bioavailability numbers for cannabis suppositories in secondary discussions online. I do not think a single numerical range is defensible for homemade products based on the primary evidence currently available.

Older experimental work shows that some rectal cannabinoid formulations can produce little systemic exposure, while later pharmaceutical formulations have produced substantial systemic THC concentrations. The apparent contradiction disappears when the formulation itself is recognized as a major variable.

The scientifically responsible statement is therefore simpler:

What about “localized” relief?

This is another area where reasonable clinical intuition can get ahead of the data.

A patient with pelvic, vaginal, or rectal symptoms may reasonably wonder whether placing a cannabinoid preparation near the symptomatic tissue could be useful. The idea has biological plausibility, and rectal or vaginal drug delivery is well established for other medications.

What has not been established is that a homemade cannabis suppository reliably creates a therapeutically useful local cannabinoid concentration, or that local exposure explains symptom improvement when patients report it.

The absence of intoxication does not prove that cannabinoids are “staying local.” A person may experience little or no psychoactive effect because systemic exposure is low, because the dose is low, because the product contains little THC, because absorption is delayed, or because of individual pharmacodynamic differences. Subjective experience alone cannot tell us where the cannabinoids went.

Where patients are most likely to consider this route

Interest in cannabinoid suppositories tends to arise around pelvic, vaginal, and lower gastrointestinal symptoms. Examples include pelvic pain, menstrual discomfort, endometriosis-associated pain, discomfort with intercourse, rectal discomfort, and symptoms occurring in the distal gastrointestinal tract.

There is biological plausibility for investigating cannabinoids in several of these areas, but the evidence for cannabis suppositories themselves remains limited. The 2025 pharmaceutical formulation study discussed endometriosis and pain as potential applications for a standardized rectal or vaginal cannabis product, but it evaluated formulation characteristics and cannabinoid release, not clinical efficacy in patients.

The same distinction matters for inflammatory bowel disease. Pharmaceutical engineering research has explored rectal drug delivery for ulcerative colitis, including sophisticated 3D-printed formulations of non-cannabinoid medications. Those studies demonstrate what targeted rectal drug delivery can accomplish as a pharmaceutical concept. They do not establish that a homemade cannabis suppository treats ulcerative colitis or Crohn’s disease.

For broader clinical background, see CED Clinic’s guides to women’s health and hormonal conditions, gastrointestinal and autoimmune conditions, and cannabis and Crohn’s disease.

Practical safety considerations

• Do not rely on milligram equivalence across routes. A 5 mg suppository, 5 mg edible, and inhaled 5 mg exposure cannot be assumed to produce equivalent systemic concentrations or effects.
• Avoid unknown-potency starting material. If the amount of THC or CBD in the starting oil is unknown, the final dose is also unknown.
• Oil can damage latex. Coconut oil and other oil-based preparations can compromise latex barrier products. Check compatibility with any contraceptive, barrier, or medical device being used concurrently.
• Known coconut allergy is a reason to choose another base. Coconut allergy is uncommon but documented. A complicated allergy history warrants individualized advice rather than assuming mucosal use will be tolerated.
• New bleeding, severe pain, infection, or unexplained symptoms deserve diagnosis first. A suppository should not become a way of masking a symptom that needs medical evaluation.
• Recent pelvic, vaginal, colorectal, or gastrointestinal surgery changes the situation. Do not insert a home preparation into healing or injured tissue without guidance from the treating clinician.
• Systemic drug interactions cannot be ruled out. Because rectal cannabinoid formulations can produce systemic exposure, it is not safe to assume that this route avoids cannabinoid interactions with other medications.
• Pregnancy requires a different threshold for experimentation. Rectal or vaginal administration should not be assumed to prevent fetal cannabinoid exposure.

When I would want a patient to ask first

I do not think every patient needs a medical appointment before experimenting with every cannabis format. I do think the threshold for guidance should become lower as the medical situation becomes more complicated.

I would want more active clinical involvement when the patient is cannabis-naive, unusually sensitive to THC, pregnant or trying to conceive, taking medications with meaningful interaction potential, immunocompromised, recovering from surgery, experiencing unexplained bleeding or pain, or treating an active gastrointestinal, gynecologic, colorectal, or pelvic diagnosis.

The same applies when a patient is trying to replace an established treatment rather than simply adding a comfort measure. Suppositories should not quietly become a substitute for evidence-based treatment of inflammatory bowel disease, infection, malignancy, endometriosis, or other conditions that require diagnosis and longitudinal care.

For more general dosing principles, see Smart Cannabis Dosing and the Cannabis Dosage and Application Guide.